Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1)
Mobile IV therapy offers: In-clinic IV therapy may be preferred by those seeking lower cost options or those located close to the clinic
Keywords: glucagon-like peptide-1 receptor agonists, neuroprotection, axonal injury, diabetic neuropathy (DN), multiple sclerosis (MS), Schwann cells, olfactory ensheathing cells, oligodendrocytes 1 Introduction Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from gut enteroendocrine cells in response to food intake, and display insulinotropic actions by stimulating specific G-protein linked GLP-1 receptor (GLP-1R) on the pancreatic cells
Novo Nordisk, Ozempics manufacturer, faces over 2,000 people claiming they developed severe gastrointestinal conditions after taking the drug
VOmax/RER or Lumen-type RER proxies: more metabolic flexibility (ability to oxidize fat at rest)
